Literature DB >> 12637940

Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.

Karoly Toth1, Vera Tarakanova, Konstantin Doronin, Peter Ward, Mohan Kuppuswamy, Jacob E Locke, Julie E Dawson, Han J Kim, William S M Wold.   

Abstract

We have described three potential adenovirus type 5 (Ad5)-based replication-competent cancer gene therapy vectors named KD1, KD3, and VRX-007. All three vectors overexpress an Ad5 protein named Adenovirus Death Protein (ADP, also named E3-11.6 K protein). ADP is required for efficient lysis of Ad5-infected cells and spread of virus from cell to cell, and thus its overexpression increases the oncolytic activity of the vectors. KD1 and KD3 contain mutations in the Ad5 E1A gene that knock out binding of the E1A proteins to cellular p300/CBP and pRB; these mutations allow KD1 and KD3 to grow well in cancer cells but not in normal cells. VRX-007 has wild-type E1A. Here we report that radiation increases the oncolytic activity of KD1, KD3, and VRX-007. This increased activity was observed in cultured cells, and it was not because of radiation-induced replication of the vectors. The combination of radiation plus KD3 suppressed the growth of A549 lung adenocarcinoma xenografts in nude mice more efficiently than radiation alone or KD3 alone. The combination of ADP-overexpressing vectors and radiation may have potential in treating cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637940     DOI: 10.1038/sj.cgt.7700555

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  15 in total

1.  A fully replication-competent adenovirus vector with enhanced oncolytic properties.

Authors:  K Toth; M Kuppuswamy; E V Shashkova; J F Spencer; W S M Wold
Journal:  Cancer Gene Ther       Date:  2010-07-02       Impact factor: 5.987

Review 2.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

3.  Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development.

Authors:  Gabriel Glockzin; Klaus Mantwill; Karsten Jurchott; Alexandra Bernshausen; Axel Ladhoff; Hans-Dieter Royer; Bernd Gansbacher; Per Sonne Holm
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  In vivo demonstration of enhanced radiotherapy using rare earth doped titania nanoparticles.

Authors:  Helen E Townley; Jeewon Kim; Peter J Dobson
Journal:  Nanoscale       Date:  2012-07-06       Impact factor: 7.790

5.  New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.

Authors:  J F Spencer; J E Sagartz; W S M Wold; K Toth
Journal:  Cancer Gene Ther       Date:  2009-05-29       Impact factor: 5.987

Review 6.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

7.  INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.

Authors:  B Ying; K Toth; J F Spencer; J Meyer; A E Tollefson; D Patra; D Dhar; E V Shashkova; M Kuppuswamy; K Doronin; M A Thomas; L A Zumstein; W S M Wold; D L Lichtenstein
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

8.  The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  B A Young; J F Spencer; B Ying; K Toth; W S M Wold
Journal:  Cancer Gene Ther       Date:  2013-08-09       Impact factor: 5.987

9.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

Review 10.  Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.

Authors:  Sean M O'Cathail; Tzveta D Pokrovska; Timothy S Maughan; Kerry D Fisher; Leonard W Seymour; Maria A Hawkins
Journal:  Front Oncol       Date:  2017-07-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.